Seredigm Corporation is a Research and Development Laboratories business in Seattle, WA.
Business Name: | Seredigm Corporation |
Categorized In: | Research and Development Laboratories |
Address: | 1616 Eastlake Avenue East # 200, Seattle, WA 98102 |
Phone Number: | (206) 957-7300 |
Contact Person: | Carl Weissman |
Website Address: | acceleratorcorp.com |
NAICS Code: | 541712 |
SIC Code: | 8731 |
Business Type: | B2B (Business to Business) |
Founding Year: | 2008 |
Employee #: | 1 to 4 |
Location Type: | Single Location |
Annual Revenue ($): | $100.000 to $499.999 |
Share This Business: | |
Similar Businesses: |
Acylin Therapeutics Inc - Seattle, WA 98102 Genewiz Inc - Seattle, WA 98102 Complex Chemicals Corp - Seattle, WA 98102 Arzeda - Seattle, WA 98102 Groove Biopharma - Seattle, WA 98102 Spi Surgical Inc - Seattle, WA 98102 Gilead Sciences Inc - Seattle, WA 98102 Tria Bioscience Corp - Seattle, WA 98102 Adaptive Biotechnologies Corporation - Seattle, WA 98102 |
Seredigm Corporation, a stable growing company under Research and Development Laboratories, is being run by Carl Weissman. Since , their sales have been favorable and consistent at $100.000 to $499.999. Company location coordinates are: 47.634694,-122.32509.
It can be reached by dialing (206) 957-7300, and you could get in touch with their sales team in 1616 Eastlake Avenue East # 200, Seattle, Washington WA 98102. Visit their website at: acceleratorcorp.com to know more about the company’s history, products and services, as well as frequently asked questions and privacy policies.
Special deals are also offered from time to time. Their professional and honest business transactions fortifies both consumers and businesses in their B2B segments.
Their modest but solid single location houses 1 to 4 staff members. All are benefiting from the company’s generous programs and sound training solutions.
You can learn more by checking their classification codes: SIC – 8731 and NAIC – 541712. Call the hotline stated above for faster transaction and queries. Seredigm Corporation would like to hear from you.